Comprehensive genomic profiling (CGP) of tumors identifies specific acquired molecular alterations, thereby enabling biomarker-directed therapies for many cancer types. Although historically performed on tumor tissue, recent efforts have focused on alternative methods of obtaining the same information.
This white paper from PGDx presents data that supports the incorporation of circulating tumor DNA (ctDNA) analysis into cancer care to increase biomarker detection and decrease time to treatment, demonstrating the concordance between tissue NGS and the PGDx elio plasma resolve assay.
Offered Free by: PGDx
See All Resources from: PGDx